GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » Cash Flow from Operations

Melodiol Global Health (ASX:ME1DE) Cash Flow from Operations : A$-8.14 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2023, Melodiol Global Health's Cash Receipts from Operating Activities was A$7.09 Mil. Its Cash Payments was A$-9.41 Mil. Its Dividends Paid was A$0.00 Mil. Its Dividends Received was A$0.00 Mil. Its Interest Paid was A$0.01 Mil. Its Interest Received was A$0.00 Mil. Its Taxes Refund Paid was A$0.00 Mil. And its Cash Flow from Others was A$0.06 Mil. In all, Melodiol Global Health's Cash Flow from Operations for the six months ended in Dec. 2023 was A$-2.26 Mil.


Melodiol Global Health Cash Flow from Operations Historical Data

The historical data trend for Melodiol Global Health's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Cash Flow from Operations Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial -10.17 -9.62 -22.38 -17.31 -8.14

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.41 -6.00 -11.31 -5.88 -2.26

Melodiol Global Health Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Melodiol Global Health's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Melodiol Global Health's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-8.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health  (ASX:ME1DE) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Melodiol Global Health's cash receipts from operating activities for the six months ended in Dec. 2023 was A$7.09 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Melodiol Global Health's cash payments for the six months ended in Dec. 2023 was A$-9.41 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Melodiol Global Health's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Melodiol Global Health's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Melodiol Global Health's cash payments for the six months ended in Dec. 2023 was A$0.01 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Melodiol Global Health's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Melodiol Global Health's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Melodiol Global Health's cash flow from others for the six months ended in Dec. 2023 was A$0.06 Mil.


Melodiol Global Health Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (ASX:ME1DE) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines